BRAF and melanoma: Notably, Stark et al., demonstrated that miR-514a is characteristic of melanoma and its overexpression inhibits NF1 expression, ultimately supporting the survival of melanoma cells with the BRAFV600E mutation, even when treated with the BRAF inhibitor PLX4032 (Stark et al., 2015[58]).